Teva Pharmaceutical Industries Ltd. said it intends to issue euro-denominated and U.S.-dollar-denominated senior notes through three Dutch finance subsidiaries, subject to market conditions. Proceeds, together with cash on hand, would fund the conditional redemption of certain existing notes, related fees and expenses, and general corporate purposes including debt repayment. The planned redemptions cover all outstanding 6.750% Senior Notes due 2028, all outstanding 7.875% and 7.375% Sustainability-Linked Senior Notes due 2029, up to $450 million of 4.750% Sustainability-Linked Senior Notes due 2027 and up to €1.25 billion of 4.375% Sustainability-Linked Senior Notes due 2030. The new notes would be unsecured senior obligations of the issuing subsidiaries and unconditionally guaranteed on a senior basis by Teva. The offering is not contingent on the redemptions, while the redemptions are expected to depend on completion of the offering.